Investigational drug · Phase 3
HS-20089
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, Platinum-sensitive Recurrent Ovarian Cancer, Fallopian Tube Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "HS-20089"
First trial start
2023
Dec 18, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-20089", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- Platinum-sensitive Recurrent Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer
Approved drugs for the same conditions: Ovarian cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-20089" as an intervention, largest first.
Hansoh BioMedical R&D CompanyIndustry
NCT06336707 · 1,048 participants (planned) · Start Apr 11, 2024 · Primary completion Apr 8, 2026
Drug: HS-20089; Adebrelimab and 2 more · For: Advanced Solid Tumors
Sites: Shanghai, China
- HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerPivotal-lookingRecruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06855069 · 468 participants (planned) · Start Mar 13, 2025 · Primary completion Mar 7, 2027
Drug: HS-20089; Paclitaxel and 2 more · For: Ovarian Cancer
Sites: Beijing, China
- Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerPivotal-lookingNot yet recruiting
Hansoh BioMedical R&D CompanyIndustry
NCT07821606 · 460 participants (planned) · Start Nov 1, 2026 · Primary completion Dec 30, 2029
Drug: HS-20089+Bevacizumab; Dose 2:arboplatin+Paclitaxel+Bevacizumab and 2 more · For: Platinum-sensitive Recurrent Ovarian Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 39 sites in all
- HS-20089 in Patients With Ovarian Cancer and Endometrial CancerPivotal-lookingRecruiting
Hansoh BioMedical R&D CompanyIndustry
NCT06014190 · 460 participants (planned) · Start Dec 18, 2023 · Primary completion Dec 31, 2025
Drug: HS-20089 · For: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 28 sites in all
Shanghai Hansoh Biomedical Co., LtdIndustry
NCT05263479 · 177 participants (planned) · Start Jan 5, 2022 · Primary completion Dec 31, 2024
Drug: HS-20089 (Phase Ia:Dose escalation ); HS-20089 (Phase Ib: Dose expansion) · For: Advanced Solid Tumor
Sites: Shanghai, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06769425 · 157 participants (planned) · Start May 7, 2025 · Primary completion May 7, 2026
Drug: HS-10502 + NHA; HS-10502 + HS-20093 and 5 more · For: Recurrent Ovarian Cancer; HER2-negative; Advanced Breast Cancer and 3 more
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.